On balance a decent update:
Positives
- Boehringer on track for delivering clinical trial results in early Q4.
- Bronchitol looking promising for US approval Q1 next calendar year.
- Progress of early stage pipeline.
- R&D incentive of $6m due by year-end.
Negatives
- The delay of the LOXL2 partnering deal to year-end is the most concerning element of the update. Limited interest?
- Annual sales of Bronchitol down approx 40% year-over-year? Looks like the long-awaited Russia approval was a fizzer. Thankfully this was offset by Aridol picking up y-o-y. Gary again implies a 'move to profitability next year' is likely, but I'm cautious.
Ann: Quarterly Shareholder Update - June 2019, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
-0.001(3.13%) |
Mkt cap ! $41.29M | |||
| Open | High | Low | Value | Volume |
| 3.2¢ | 3.2¢ | 3.1¢ | $21.44K | 688.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1446000 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 41994 | 3 |
View Market Depth
| Last trade - 14.16pm 16/08/2024 (20 minute delay) ? |
| SNT (ASX) Chart |